Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.96B 3.68B 3.38B 6.38B 434B 6.48B 43.39B 17.03B 216B 17.09B 16.71B 725B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.08B 3.8B 3.49B 6.59B 449B 6.69B 44.81B 17.59B 223B 17.65B 17.26B 749B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+1.40%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 6.28
Extreme 6.28
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Fiscal year

Chief Executive Officer

225,000 0.0727%
2/1/26 Tax

General Counsel

43,109 0.0139%
2/1/26 Tax

Executive/Senior Manager

30,007 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+141.90%+6.39% 4.55B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.33%+0.97%+68.59%+92.51% 25.5B
Weighted average by Cap. -1.56%+2.00%+78.10%+125.78%

Financials

2024 2025
Net sales 528M 459M 427M 392M 741M 50.43B 753M 5.04B 1.98B 25.11B 1.98B 1.94B 84.19B 634M 551M 513M 471M 890M 60.54B 903M 6.05B 2.37B 30.14B 2.38B 2.33B 101B
Net income -56.11M -48.77M -45.4M -41.68M -78.71M -5.36B -79.93M -535M -210M -2.67B -211M -206M -8.94B -27.11M -23.57M -21.94M -20.14M -38.03M -2.59B -38.62M -259M -101M -1.29B -102M -99.58M -4.32B
Net Debt 194M 168M 157M 144M 272M 18.49B 276M 1.85B 725M 9.21B 727M 711M 30.87B 149M 129M 120M 111M 209M 14.21B 212M 1.42B 557M 7.07B 559M 547M 23.72B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock